Mylan N.V., formerly Mylan Inc., is a global pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. Mylan operates in two segments: Generics and Specialty. Mylan applies one global quality standard across our facilities, and across our product line regardless of market. At Mylan, whether it’s a medication for millions or for a handful of people our priorities are to meet or exceed industry standards.

Company Growth (employees)
Type
Public
HQ
Hatfield, GB
Founded
1961
Size (employees)
35,000 (est)
Website
mylan.com
Mylan was founded in 1961 and is headquartered in Hatfield, GB

Key People/Management at Mylan

Heather Bresch

Heather Bresch

Chief Executive Officer

Mylan Office Locations

Mylan has an office in Hatfield
Hatfield, GB (HQ)
Mosquito Way

Mylan Financials and Metrics

Mylan Financials

Mylan's revenue was reported to be $7.6 b in FY, 2014 which is a 12% increase from the previous period.
USD

Revenue (FY, 2014)

7.6 b

Revenue growth (FY, 2013 - FY, 2014), %

12%

Gross profit (FY, 2014)

3.5 b

Gross profit margin (FY, 2014), %

45%

Net income (FY, 2014)

933.1 m

Market capitalization (20-Oct-2017)

20.7 b

Closing share price (20-Oct-2017)

38.3

Cash (31-May-2016)

28.7 k
Mylan's current market capitalization is $20.7 b.
USDFY, 2013FY, 2014

Revenue

6.9 b7.6 b

Revenue growth, %

12%

Cost of goods sold

3.9 b4.2 b

Gross profit

3 b3.5 b
GBPFY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Cash

2.5 k5.9 k1.8 k163325.1 k5.2 k28.9 k15.3 k28.7 k

Accounts Receivable

9753722.5 k17.4 k5.4 k5 k9.3 k20 k12.7 k

Inventories

1.7 b1.7 b

Current Assets

3.4 k5.9 k2.2 k2.6 k17.4 k10.5 k10.2 k38.1 k35.3 k41.4 k
    USDFY, 2013FY, 2014

    Net Income

    626.5 m933.1 m

    Depreciation and Amortization

    516 m566.6 m

    Accounts Receivable

    (550 m)(940 m)

    Inventories

    (160 m)(150 m)
    Y, 2016

    Financial Leverage

    484.1 x
    Show all financial metrics

    Mylan Market Value History

    Mylan Job Categories

    Mylan Median Salaries

    Source: 123 public H-1B filings from Mylan

    Traffic Overview of Mylan

    Mylan Online and Social Media Presence

    Mylan News and Updates

    California deals pharma a double whammy with signing of copay coupon bill

    California Gov. Jerry Brown signed a new regulation limiting copay couponing on Monday, dealing a second key loss for the industry in the state.

    Mylan and Biocon biosimilar of Amgen’s Neulasta hit with manufacturing-related CRL

    The FDA, which had already criticized the plant where Biocon is producing biosimilars for the U.S. market, has now issued it and partner Mylan a complete response letter tied to manufacturing for one of them.

    Teva scrambles to match 30% Copaxone discounts from Mylan's knockoff: analyst

    Just how much Mylan’s generic of 40-mg multiple sclerosis blockbuster Copaxone ends up hurting Teva depends on the knockoff’s pricing, and on Monday one analyst offered a window into how things are playing out so far.

    Mylan piles generic Copaxone pain on Teva as partner Synthon nabs EU green light

    Just two days after Teva learned Mylan had won an FDA approval for its long-acting Copaxone generic, Mylan’s European partner announced it’d be giving Teva trouble across the pond, too.

    Mylan surprises analysts, Teva with long-delayed Copaxone approvals

    Mylan has long been frustrated by delays for a pair of high-profile generic products. But on Tuesday evening, it picked up an approval for one of them—and it came at Teva’s expense.

    FDA’s Gottlieb pushes new generics rules to encourage price competition

    FDA Commissioner Scott Gottlieb, M.D., is embarking on a series of initiatives aimed directly at bringing down rising drug prices. Yesterday he outlined the first policies, which are aimed specifically at “complex generic drugs.” As Gottlieb explained, inventors of complex drugs have almost complete…
    Show more

    Mylan Company Life and Culture

    You may also be interested in